NexImmune, Inc.

NEXI

US65344D2080

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:59:59 15/07/2024 BST			5-day change	1st Jan Change
2.37 ^USD	-20.47%		-0.84%	+6.76%

12:00am	NexImmune, Inc.(NasdaqCM:NEXI) dropped from S&P TMI Index	CI
07-11	NexImmune, Inc.(NasdaqCM:NEXI) dropped from NASDAQ Composite Index	CI

NexImmune, Inc.(NasdaqCM:NEXI) dropped from S&P TMI Index

July 15, 2024

Latest news about NexImmune, Inc.

NexImmune, Inc.(NasdaqCM:NEXI) dropped from S&P TMI Index	15/07/2024	CI
NexImmune, Inc.(NasdaqCM:NEXI) dropped from NASDAQ Composite Index	07-10	CI
NexImmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20	CI
North American Morning Briefing : Stock Futures -2-	04-17	DJ
NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
North American Morning Briefing : Traders Await -2-	04-10	DJ
NexImmune, Inc. Announces CFO Changes	04-05	CI
NexImmune, Inc. Announces Executive Changes	04-05	CI
North American Morning Briefing : Powell Awaited -2-	04-03	DJ
Top Premarket Decliners	01-04	MT
Top Premarket Decliners	12-04	MT
Wall Street Set to Open Lower Friday as Investors Await Economic Data, Powell Speech	12-01	MT
Top Premarket Gainers	12-01	MT
Investors Look Ahead to Powell Speech as US Futures Trend Lower Friday	12-01	MT
North American Morning Briefing : Stocks Futures -2-	11-20	DJ
NexImmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-17	CI
Top Premarket Decliners	11-06	MT
Top Premarket Decliners	11-03	MT
NexImmune Extends Partnership With Yale, JDRF for Type 1 Diabetes	24/10/23	MT
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes	24/10/23	CI
Sector Update: Health Care Stocks Softer Late Afternoon	18/10/23	MT
Sector Update: Health Care Stocks Sliding Wednesday Afternoon	18/10/23	MT
NexImmune Implements 1-for-25 Reverse Stock Split	18/10/23	MT
NexImmune Cutting Over Half of Workforce to Fund Development of Novel Therapeutic Candidates	31/08/23	MT
NexImmune, Inc. Announces Executive Changes, Effective as of September 2, 2023	31/08/23	CI

NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the bodyâs own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
NEXIMMUNE, INC.	+6.76%	3.25M
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	127B
ARGENX SE	+24.16%	27.67B
BIONTECH SE	-20.17%	20.33B
GENMAB A/S	-16.06%	16.79B
BEIGENE, LTD.	-18.07%	15.63B
WUXI APPTEC CO., LTD.	-47.70%	14.65B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.43B
INSMED INCORPORATED	+149.98%	12.49B

Bio Therapeutic Drugs

NexImmune, Inc.

Equities

NEXI

US65344D2080

Biotechnology & Medical Research

NexImmune, Inc.(NasdaqCM:NEXI) dropped from S&P TMI Index

Latest news about NexImmune, Inc.

Chart NexImmune, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs